
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K/A
(AMENDMENT NO. 1)**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 17, 2022**

RESHAPE LIFESCIENCES INC.

(Exact name of registrant as specified in its charter)

Delaware **1-37897** **26-1828101**
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

1001 Calle Amanecer **92673**
San Clemente, CA
(Address of principal executive offices) (Zip Code)

(949) 429-6680
(Registrant's telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Class	Trading Symbol	Name of Exchange on which Registered
Common stock, \$0.001 par value per share	RSLS	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On March 17, 2022, ReShape Lifesciences Inc. filed a Current Report on Form 8-K (the “Original Report”) and issued a press release announcing certain preliminary results for the year ended December 31, 2021. The sole purpose of this amendment is to correct the time of the conference call and webcast referred to in the press release. A copy of the corrected press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated herein reference.

The information furnished herewith pursuant to Item 2.02 of this Current Report and in Exhibit 99.1 hereto is being “furnished” in accordance with General Instruction B.2 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated March 17, 2022
104	Cover Page Interactive Data File (embedded with inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RESHAPE LIFESCIENCES INC.

By: /s/ Tom Stankovich

Tom Stankovich
Chief Financial Officer

Dated: March 21, 2022

ReShape Lifesciences™ to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

Full Year Revenue Increased by Approximately 20%, from \$11.3 M to \$13.6 M

\$22.8 M in Cash and Cash Equivalents as of December 31, 2021

Company Eliminated All Debt from Balance Sheet

Webcast to be Held at 5:30 pm ET on Monday, March 28, 2022

SAN CLEMENTE, Calif., March 17, 2022 -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the year-ended December 31, 2021, including a corporate update, on Monday, March 28, 2022, after-market. A conference call and webcast will be held at 5:30 pm ET.

“2021 was a transformative year for ReShape, punctuated by our listing on Nasdaq and the highly anticipated re-launch of the Lap-Band®,” stated Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences. “As a result of our efforts, 2021 revenues increased by 20%, to \$13.6 million, we were able to eliminate all debt from our balance sheet including our final \$3 million obligation to Apollo Endosurgery for the purchase of the Lap-Band in December of 2018, and our cash balance at year-end was approximately \$23 million. In the latter half of the year, we also kicked-off our national, direct-to-consumer television and print marketing campaign and virtual media tour. The results have been very strong and encouraging, and we look forward to providing updated metrics, soon.”

To participate in the conference call, dial 1-877-280-7473 (US/Canada) or 1-707-287-9370 (international) and enter passcode 5376956. A live link to the webcast will be available on the “Events and Presentations” section of ReShape’s website at: <https://ir.reshapelifesciences.com/events-and-presentations>.

A replay will be available approximately two hours after the call, for one week. The replay number is 1-855-859-2056, conference ID 5376956. An archived replay will also be available at: <https://ir.reshapelifesciences.com/events-and-presentations>.

About ReShape Lifesciences™

ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. For more information, please visit www.reshapelifesciences.com

CONTACTS:

Company Contact:

Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Relations Contact:

Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
